Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity
PDF | HTML | How to cite
Metrics: PDF 1856 views | HTML 2688 views | ?
Charles H. Adelmann1, Grace Ching1, Lili Du1, Rachael C. Saporito1, Varun Bansal1, Lindy J. Pence1, Roger Liang1, Woojin Lee1, Kenneth Y. Tsai1,2,3
1Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA
2Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA
3Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA
Kenneth Y. Tsai, email: [email protected]
Keywords: BRAF, squamous cell carcinoma, small molecule inhibitor, paradoxical ERK, melanoma
Received: November 26, 2015 Accepted: March 04, 2016 Published: March 25, 2016
BRAF inhibitor (BRAFi) therapy is associated with the induction of neoplasia, most commonly cutaneous squamous cell carcinoma (cuSCC). This toxicity is explained in part by “paradoxical ERK activation,” or the hyperactivation of ERK signaling by BRAFi in BRAF wild-type cells. However, the rate of cuSCC induction varies widely among BRAFi. To explore this mechanistically, we profiled paradoxical ERK activation by vemurafenib, dabrafenib, encorafenib (LGX818), and PLX8394, demonstrating that vemurafenib induces ERK activation the greatest, while dabrafenib and encorafenib have higher “paradox indices”, defined as the pERK activation EC80 divided by the IC80 against A375, corresponding to wider therapeutic windows for achieving tumor inhibition without paradoxical ERK activation. Our results identify differences in the paradox indices of these compounds as a potential mechanism for the differences in cuSCC induction rates and highlight the utility of using ERK activity as a biomarker for maximizing the clinical utility of BRAFi.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.